Target Anti-Factor Xa Range for Enoxaparin Prophylaxis in Pediatric Nephrotic Syndrome
For DVT prophylaxis in a child with nephrotic syndrome, target a peak anti-factor Xa level of 0.1–0.3 IU/mL when using enoxaparin. This prophylactic range is lower than the therapeutic range of 0.5–1.0 IU/mL used for treating established thrombosis 1.
Dosing Strategy
Start with age-appropriate prophylactic dosing based on the 2025 ASH/ISTH guidelines 1:
- <3 months: Begin with 0.75 mg/kg subcutaneously every 12 hours
- 3 months to 1 year: 0.5–0.75 mg/kg every 12 hours
- 1–5 years: 0.5–0.6 mg/kg every 12 hours
- >5 years: 0.5 mg/kg every 12 hours
Check the first anti-factor Xa level 4 hours after the second or third dose (range 3.5–6 hours acceptable) 1.
Monitoring and Adjustment
Adjust dosing using this nomogram for prophylactic levels 2:
- <0.1 IU/mL: Increase dose by 25%
- 0.1–0.3 IU/mL: Therapeutic target achieved—no change needed
- >0.3 IU/mL: Decrease dose by 10–20%
Recheck anti-factor Xa 4 hours after any dose adjustment 1.
Critical Considerations in Nephrotic Syndrome
Children with nephrotic syndrome present unique pharmacokinetic challenges that make monitoring essential:
Nephrotic syndrome increases thrombotic risk through urinary loss of antithrombin III, protein C, and protein S, combined with elevated fibrinogen and platelet hyperreactivity 3. Despite this high-risk state, recent evidence shows that routine anticoagulation prophylaxis (warfarin, heparin, or aspirin) did not significantly reduce thrombotic events in a retrospective cohort 3. However, the 2021 ERKNet-ESPN consensus acknowledges that thromboprophylaxis remains commonly used in clinical practice, particularly in high-risk scenarios such as central venous lines.
Altered drug clearance is common: Nephrotic patients may have unpredictable enoxaparin pharmacokinetics due to hypoalbuminemia, proteinuria, and variable renal function. This makes empiric dosing without monitoring potentially dangerous—you may underdose (leaving the patient unprotected) or overdose (risking bleeding).
Younger children require higher weight-based doses to achieve target levels 1, 4, 5. Infants under 1 year and children 1–2 years consistently need more frequent dose adjustments 5.
Common Pitfalls to Avoid
Do not use therapeutic ranges (0.5–1.0 IU/mL) for prophylaxis—this significantly increases bleeding risk without proven additional benefit 1.
Do not skip monitoring in nephrotic patients—the altered pharmacokinetics make "standard" dosing unreliable. Even though some advocate for fixed dosing without monitoring in general pediatric populations, this has not been validated and is particularly risky in nephrotic syndrome 1.
Avoid aspirin in nephrotic syndrome—it may induce acute kidney injury and should be used with extreme caution, avoiding high doses entirely 3.
Do not assume once-daily dosing is adequate—pediatric data show significant variability and inadequate trough levels with once-daily enoxaparin, particularly in younger children 1. Twice-daily dosing is preferred for consistent prophylaxis.
Monitor for hypoalbuminemia and correct electrolytes—very low magnesium and calcium levels may promote thrombosis and should be supplemented 3.
Duration of Prophylaxis
The optimal duration remains unclear, but consider continuing prophylaxis while:
- Central venous catheters remain in place
- Severe hypoalbuminemia persists (albumin <2.0 g/dL)
- The patient is immobilized or has other concurrent thrombotic risk factors
The Finnish experience with long-term warfarin prophylaxis (INR 2–2.5) in congenital nephrotic syndrome showed no substantial bleeding increase, though this was not validated in controlled trials 3. For enoxaparin prophylaxis, there is no established evidence-based duration—clinical judgment based on resolution of nephrotic state and thrombotic risk factors should guide therapy.
Bleeding Risk
Prophylactic-dose enoxaparin carries low bleeding risk. In the MIS-C cohort using target anti-Xa 0.1–0.3 IU/mL, only 4.2% experienced clinically relevant non-major bleeding with no major bleeding events 2. Major bleeding with prophylactic LMWH in pediatric trials ranges from 0–2.4% 1.